Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

Brief description of study

The purpose of this research study is to compare the efficacy an investigational drug called crenolanib (a drug that has not been approved by the FDA or any other regulatory agency for any use, also referred to as study drug in this consent) with midostaurin (RYDAPT®) which has been approved by the FDA for treatment of newly diagnosed acute myeloid leukemia patients with FLT3 mutations. We are asking you to take part in this research study because you have taken part in the pre-screening procedures where it was confirmed that you are a newly diagnosed acute myeloid leukemia patient with FLT3 mutations.


Clinical Study Identifier: s18-01120
ClinicalTrials.gov Identifier: NCT03258931
Principal Investigator: Mohammad Maher Abdul Hay
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.